Skip to main content
SpringerLink
Log in

T2238C Atrial Natriuretic Peptide Gene Variant and the Response to Antiplatelet Therapy in Stable Ischemic Heart Disease Patients

  • Original Article
  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

The T2238C variant of the ANP gene is associated with higher risk of major cardiovascular events. The purpose of this study is to investigate if this polymorphism influences the response to antiplatelet agents and it is responsible of increased platelet reactivity, thus contributing to the adverse outcome. In patients undergoing elective percutaneous coronary intervention (PCI), loaded with antiplatelets, blood samples were withdrawn for genotyping, platelet reactivity assessment and for troponin T measurement to investigate the association between the polymorphism with residual platelet reactivity and with the incidence of PPMI. No significant differences in platelet reactivity nor in PPMI incidence were observed between groups. Nevertheless, higher ARU, PRU, and % PI were detected in diabetic patients, with PRU significantly higher in carriers versus non-carriers. We observed increased residual platelet reactivity exclusively in diabetic carriers of the T2238C variant undergoing elective PCI, suggesting the need of a more effective platelet inhibition in this category of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

ANP:

Atrial natriuretic peptide

CAD:

Coronary artery disease

PCI:

Percutaneous coronary intervention

PPMI:

Peri-procedural myocardial injury

PRU:

P2Y12 reaction units

ARU:

Aspirin reaction units

PI:

% P2Y12 platelet inhibition

HPR:

High platelet reactivity

References

  1. Rubattu, S., Sciarretta, S., & Volpe, M. (2014). Atrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases. Clinical Science, 127, 1–13.

    Article  CAS  PubMed  Google Scholar 

  2. Scarpino, S., Marchitti, S., Stanzione, R., Evangelista, A., Di Castro, S., Savoia, C., Quarta, G., Sciarretta, S., Ruco, L., Volpe, M., & Rubattu, S. (2009). ROS-mediated differential effects of the human atrial natriuretic peptide T2238C genetic variant on endothelial cells in vitro. Journal of Hypertension, 27, 1804–1813.

    Article  CAS  PubMed  Google Scholar 

  3. Sciarretta, S., Marchitti, S., Bianchi, F., Moyes, A., Barbato, E., Di Castro, S., Stanzione, R., Cotugno, M., Castello, L., Calvieri, C., Eberini, I., Sadoshima, J., Hobbs, A. J., Volpe, M., & Rubattu, S. (2013). The C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling. Circulation Research, 112, 1355–1364.

    Article  CAS  PubMed  Google Scholar 

  4. Rubattu, S., Marchitti, S., Bianchi, F., Di Castro, S., Stanzione, R., Cotugno, M., Bozzao, C., Sciarretta, S., & Volpe, M. (2014). The C2238/αANP variant is a negative modulator of both viability and function of coronary artery smooth muscle cells. PLoS One, 9, e113108.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Carnevale, R., Pignatelli, P., Frati, G., Nocella, C., Stanzione, R., Pastori, D., Marchitti, S., Valenti, V., Santulli, M., Barbato, E., Strisciuglio, T., Schirone, L., Vecchione, C., Violi, F., Volpe, M., Rubattu, S., & Sciarretta, S. (2017). C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. Scientific Reports, 7, 3797.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Gruchala, M., Ciećwierz, D., Wasag, B., Targoński, R., Dubaniewicz, W., Nowak, A., Sobiczewski, W., Ochman, K., Romanowski, P., Limon, J., & Rynkiewicz, A. (2003). Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. American Heart Journal, 145, 125–131.

    Article  CAS  PubMed  Google Scholar 

  7. Rubattu, S., Stanzione, R., Di Angelantonio, E., Zanda, B., Evangelista, A., Tarasi, D., Gigante, B., Pirisi, A., Brunetti, E., & Volpe, M. (2004). Atrial natriuretic peptide gene polymorphisms and the risk of ischemic stroke in humans. Stroke, 35, 814–818.

    Article  CAS  PubMed  Google Scholar 

  8. Barbato, E., Bartunek, J., Mangiacapra, F., Sciarretta, S., Stanzione, R., Delrue, L., Cotugno, M., Marchitti, S., Iaccarino, G., Sirico, G., Di Castro, S., Evangelista, A., Lambrechts, D., Sinnaeve, P., De Bruyne, B., Van De Werf, F., Janssens, S., Fox, K. A., Wijns, W., Volpe, M., & Rubattu, S. (2012). Influence of T2238C atrial natriuretic peptide gene variant on coronary artery disease. Journal of the American College of Cardiology, 59, 1763–1770.

    Article  CAS  PubMed  Google Scholar 

  9. Rubattu, S., De Giusti, M., Farcomeni, A., Abbolito, S., Comito, F., Cangianiello, S., Greco, E. S., Dito, E., Pagliaro, B., Cotugno, M., Stanzione, R., Marchitti, S., Bianchi, F., Di Castro, S., Battistoni, A., Burocchi, S., Caprinozzi, M., Pierelli, G., Sciarretta, S., & Volpe, M. (2016). T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients. Journal of Cardiovascular Medicine, 17, 601–607.

    Article  CAS  PubMed  Google Scholar 

  10. Cannone, V., Huntley, B. K., Olson, T. M., Heublein, D. M., Scott, C. G., Bailey, K. R., Redfield, M. M., Rodeheffer, R. J., & Burnett Jr., J. C. (2013). Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study. Hypertension, 62, 860–865.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mangiacapra, F., Peace, A., Barbato, E., Patti, G., Gatto, L., Ricottini, E., De Bruyne, B., Di Sciascio, G., & Wijns, W. (2014). Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. Platelets, 25, 348–356.

    Article  CAS  PubMed  Google Scholar 

  12. Tantry, U. S., Bonello, L., Aradi, D., Price, M. J., Jeong, Y. H., Angiolillo, D. J., Stone, G. W., Curzen, N., Geisler, T., Ten Berg, J., Kirtane, A., Siller-Matula, J., Mahla, E., Becker, R. C., Bhatt, D. L., Waksman, R., Rao, S. V., Alexopoulos, D., Marcucci, R., Reny, J. L., Trenk, D., Sibbing, D., Gurbel, P. A., & Working Group on On-Treatment Platelet Reactivity. (2013). Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. Journal of the American College of Cardiology, 62, 2261–2273.

    Article  CAS  PubMed  Google Scholar 

  13. Thygesen, K., Alpert, J. S., White, H. D., Jaffe, A. S., Katus, H. A., Apple, F. S., Lindahl, B., Morrow, D. A., Chaitman, B. A., Clemmensen, P. M., Johanson, P., Hod, H., Underwood, R., Bax, J. J., Bonow, R. O., Pinto, F., Gibbons, R. J., Fox, K. A., Atar, D., Newby, L. K., Galvani, M., Hamm, C. W., Uretsky, B. F., Steg, P. G., Wijns, W., Bassand, J. P., Menasché, P., Ravkilde, J., Ohman, E. M., Antman, E. M., Wallentin, L. C., Armstrong, P. W., Simoons, M. L., Januzzi, J. L., Nieminen, M. S., Gheorghiade, M., Filippatos, G., Luepker, R. V., Fortmann, S. P., Rosamond, W. D., Levy, D., Wood, D., Smith, S. C., Hu, D., Lopez-Sendon, J. L., Robertson, R. M., Weaver, D., Tendera, M., Bove, A. A., Parkhomenko, A. N., Vasilieva, E. J., Mendis, S., & ESC Committee for Practice Guidelines (CPG). (2012). Third universal definition of myocardial infarction. European Heart Journal, 33, 2551–2567.

    Article  PubMed  Google Scholar 

  14. Angiolillo, D. J., Bernardo, E., Sabate, M., Jimenez-Quevedo, P., Costa, M. A., Palazuelos, J., Hernández-Antolin, R., Moreno, R., Escaned, J., Alfonso, F., Bañuelos, C., Guzman, L. A., Bass, T. A., Macaya, C., & Fernandez-Ortiz, A. (2007). Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American College of Cardiology, 50, 1541–1547.

    Article  PubMed  Google Scholar 

  15. Schneider, D. J. (2009). Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care, 32, 525–527.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mangiacapra, F., Patti, G., Peace, A., Gatto, L., Vizzi, V., Ricottini, E., D'Ambrosio, A., Muller, O., Barbato, E., & Di Sciascio, G. (2010). Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. The American Journal of Cardiology, 106(5), 619–623.

    Article  CAS  PubMed  Google Scholar 

  17. Rubattu, S., Sciarretta, S., Valenti, V., Stanzione, R., & Volpe, M. (2008). Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. American Journal of Hypertension, 21, 733–741.

    Article  CAS  PubMed  Google Scholar 

  18. Volpe, M., Rubattu, S., & Burnett Jr., J. (2014). Natriuretic peptides in cardiovascular diseases: current use and perspectives. European Heart Journal, 35, 419–425.

    Article  CAS  PubMed  Google Scholar 

  19. Rubattu, S., Sciarretta, S., Morriello, A., Calvieri, C., Battistoni, A., & Volpe, M. (2010). NPR-C: a component of the natriuretic peptide family with implications in human diseases. Journal of Molecular Medicine, 88, 889–897.

    Article  CAS  PubMed  Google Scholar 

  20. Authors/Task Force members, Windecker, S., Kolh, P., Alfonso, F., Collet, J. P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., Kappetein, A. P., Kastrati, A., Knuuti, J., Landmesser, U., Laufer, G., Neumann, F. J., Richter, D. J., Schauerte, P., Sousa Uva, M., Stefanini, G. G., Taggart, D. P., Torracca, L., Valgimigli, M., Wijns, W., & Witkowski, A. (2014). 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 35, 2541–2619.

    Article  Google Scholar 

  21. Noé, L., Peeters, K., Izzi, B., Van Geet, C., & Freson, K. (2010). Regulators of platelet cAMP levels: clinical and therapeutic implications. Current Medicinal Chemistry, 17, 2897–2905.

    Article  PubMed  Google Scholar 

  22. Wiviott, S. D., Trenk, D., Frelinger, A. L., O'Donoghue, M., Neumann, F. J., Michelson, A. D., et al. (2007). Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation, 116(25), 2923–2932.

    Article  CAS  PubMed  Google Scholar 

  23. Franchi, F., Rollini, F., Aggarwal, N., Hu, J., Kureti, M., Durairaj, A., et al. (2016). Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: The OPTIMUS (optimizing antiplatelet therapy in diabetes mellitus)-4 study. Circulation, 134(11), 780–792.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

A research grant provided by the Cardiopath PhD program is acknowledged for supporting Dr. T. Strisciuglio.

Funding

This work was supported by a grant from the Italian Ministry of Health and from the 5‰ grant.

Author information

Authors and Affiliations

  1. Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy

    Teresa Strisciuglio, Emanuele Barbato, Chiara De Biase, Giuseppe Di Gioia & Bruno Trimarco

  2. Cardiovascular Research Center Aalst, Aalst, Belgium

    Emanuele Barbato, Wiliam Wijns & Leen Delrue

  3. IRCCS Neuromed, Pozzilli, Isernia, Italy

    Maria Cotugno, Rosita Stanzione, Sebastiano Sciarretta, Massimo Volpe & Speranza Rubattu

  4. Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy

    Sebastiano Sciarretta

  5. Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Sant’Andrea Hospital, Rome, Italy

    Massimo Volpe & Speranza Rubattu

Authors
  1. Teresa Strisciuglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emanuele Barbato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiara De Biase
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Di Gioia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Cotugno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rosita Stanzione
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bruno Trimarco
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sebastiano Sciarretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Massimo Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wiliam Wijns
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Leen Delrue
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Speranza Rubattu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emanuele Barbato.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest. This study complied with the Declaration of Helsinki and was approved by the local ethics Committee. Each patient provided informed consent to the study.

Additional information

Associate Editor Paul J. R. Barton oversaw the review of this article

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Strisciuglio, T., Barbato, E., De Biase, C. et al. T2238C Atrial Natriuretic Peptide Gene Variant and the Response to Antiplatelet Therapy in Stable Ischemic Heart Disease Patients. J. of Cardiovasc. Trans. Res. 11, 36–41 (2018). https://doi.org/10.1007/s12265-017-9774-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-017-9774-9

Keywords

Search

Navigation